Key result
Cardiovascular toxicity associated with anti-cancer treatment requires regular monitoring with cardiac imaging and biomarkers for early detection and management.
Answers are grounded in this paper and cite their sources.
This review outlines the mechanisms and clinical management of cardiovascular toxicities related to anti-cancer therapies, highlighting the importance of early detection through cardiac imaging.
Cardiovascular (CV) toxicity associated with anti-cancer treatment is commonly encountered and raises critical problems that often result in serious morbidity or mortality. Most cardiac toxicities are related to the cumulative dose of chemotherapy; however, the type of chemotherapy, concomitant agents, and/or conventional CV risk factors have been frequently implicated in CV toxicity. Approximately half of the patients exhibiting CV toxicity receive an anthracycline-based regimen. Therefore, serologic biomarkers or cardiac imagings are important during anti-cancer treatment for early detection and the decision of appropriate management of cardiotoxicity. However, given the difficulty in determining a causal relationship, a multidisciplinary collaborative approach between cardiologists and oncologists is required. In this review, we summarize the CV toxicity and focus on the role of cardiac imaging in management strategies for cardiotoxicity associated with anti-cancer treatment.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) conducted a review in Cardiovascular toxicity related to anti-cancer treatment. Anti-cancer treatment was evaluated. Cardiovascular toxicity associated with anti-cancer treatment requires regular monitoring with cardiac imaging and biomarkers for early detection and management.
Synapse has enriched 10 related papers. Consider them for comparative context: